Navigation Links
Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009
Date:8/6/2009

-- 152,873 (25,450) 127,423 --------------------------------- --------------------------------------- EXPENSES License and royalty fees 5,474 - 5,474 Cost of products sold 49,648 (896) b 48,752 Research and development 12,930 (1,152) c 11,778 Selling, general and administrative 41,178 (5,131) d 36,047 Depreciation and amortization 16,560 (14,834) e 1,726 In-process research and development - - - --------------------------------- --------------------------------------- 125,790 (22,013) 103,777 --------------------------------- --------------------------------------- Operating income (loss) 27,083 (3,437) 23,646 --------------------------------- --------------------------------------- Other income (expenses): Foreign exchange (loss) gain (709) 709 g - Investment and other income (loss) (615) 676 h 61 Loss on sale/write-down of investments - - - Interest expense on long-term debt (19,685) 1,368 j (18,317) --------------------------------- --------------------------------------- --------------------------------- --------------------------------------- (21,009) 2,753 (18,256) --------------------------------- --------------------------------------- --------------------------------- --------------------------------------- Income (loss) before income taxes 6,074 (684) 5,390 Income tax expense (recovery) 5,507 765 k 6,272 ----------------------------
'/>"/>
SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28

Related biology technology :

1. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
2. Angiotech receives favourable patent decision from New Zealands Intellectual Property Office
3. Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation
4. Angiotech to participate in UBS Global Life Sciences Conference
5. Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial
6. Angiotech Receives CE Mark Approval of Quill(TM) SRS MONODERM(TM), a New Rapidly Resorbing Suture Product Line
7. Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook
8. Angiotech to participate in Bank of America 2007 Credit Conference
9. Angiotech to participate in RBC 2007 Healthcare Conference
10. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
11. Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
... (Amex: ETC ) ("ETC" or the "Company") ... two BARA-MED(R) XD,Monoplace Hyperbaric Chambers at Christus Spohn, ... Christi, Texas, in 1905 and is,the largest and ... The,facility offers South Texans a full range of ...
... SAN DIEGO, Sept. 23 Halozyme Therapeutics,Inc. (Nasdaq: ... products targeting the extracellular matrix, today,announced that Douglas ... Vice,President, Endocrinology Clinical Development., "I am thrilled ... caliber,and achievement to the Halozyme leadership team. He ...
... Development of Novel Infectious ... Disease Diagnostic Platform -, WOBURN, ... a $4.5 million equity investment from BD (Becton, Dickinson,and Company) ... development of a novel infectious disease diagnostic,platform. The collaboration will ...
Cached Biology Technology:Environmental Tectonics Corporation Announces a Multiple Sale for Monoplace Hyperbaric Chambers 2Environmental Tectonics Corporation Announces a Multiple Sale for Monoplace Hyperbaric Chambers 3Halozyme Therapeutics Appoints Head of Endocrinology Clinical Development 2Halozyme Therapeutics Appoints Head of Endocrinology Clinical Development 3Halozyme Therapeutics Appoints Head of Endocrinology Clinical Development 4U.S. Genomics Inc. Receives $4.5 Million Investment from BD 2U.S. Genomics Inc. Receives $4.5 Million Investment from BD 3
(Date:11/21/2014)... 2014   Atmel® Corporation (NASDAQ: ... touch technology solutions, today launched the industry,s first family ... widest V cc range from 1.7V to 5.5V. ... I 2 C bus communication speeds, and are available ... them ideal for consumer, industrial, computer, and medical applications. ...
(Date:11/18/2014)... , Nov. 18, 2014   EyeLock Inc. ... solutions, and MorphoTrust USA (Safran), a ... today announced a strategic partnership to offer comprehensive ... vehicle administration (MVA), airport screening and financial services ... solutions, MorphoTrust serves consumers through a nationwide network ...
(Date:11/10/2014)... store shelves in early 2010, and people have used ... can be tossed into a washing machine without ever ... convenience, though, has come with risks for young children. ... Hospital found that from 2012 through 2013, U.S. poison ... 6 years of age swallowing, inhaling, or otherwise being ...
Breaking Biology News(10 mins):Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3Study finds laundry detergent pods, serious poisoning risk for children 2
... of ice, a minimally invasive interventional radiology treatment called ... damage, according to data being presented at the Society ... Orleans. "Cryoneurolysis could have big implications for the ... be unbearable and is very difficult to treat," said ...
... WEST ORANGE, N.J.The State of Spinal Cord Injury: Latest ... Recovery will be held on Wednesday, April 17, 2013, ... Pleasant Valley Way, West Orange, N.J. This special Grand ... Cord Injury System (NNJSCIS) and the Spinal Cord Injury ...
... have revealed the mechanism that causes a slime to ... antibiotics. When under threat, some bacteria can shield ... biofilm. It is made up of communities of bacteria ... cause dental plaque and sinusitis; in healthcare, biofilms can ...
Cached Biology News:Freezing nerves knocks pain out cold 2The State of Spinal Cord Injury Grand Rounds 2Secrets of bacterial slime revealed 2
384 Cluster Tube Racks...
The antibody recognizes the peptide sequence ESESQGPK (aa 441-448) of human class III beta-tubulin specific for neurones....
... Partially purified chicken intestinal cytoplasmic 1,25-(OH)2D3 ... receptor (VDR) from human, rat, mouse, ... This antibody does not cross-react ... MA1-710 detects both the occupied and ...
... compact, highly versatile power supply. Capable of producing ... power supply is ideal for PAGE, SDS-PAGE, DNA ... types of small format transfer apparatus. It is ... current with a continuously variable output in either ...
Biology Products: